Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL.

A. Morilla, D. Gonzalez de Castro, I. Del Giudice, N. Osuji, M. Else, R. Morilla, V. Brito Babapulle, H. Rudenko, E. Matutes, C. Dearden, D. Catovsky, G.J. Morgan

Research output: Contribution to journalArticlepeer-review

39 Citations (Scopus)


ZAP-70, CD38 and IGHV mutations have all been reported to have prognostic impact in chronic lymphocytic leukemia (CLL), both individually and in paired combinations. We aimed to determine whether the combination of all three factors provided more refined prognostic information concerning the treatment-free interval (TFI) from diagnosis. ZAP-70, CD38 and IGHV mutations were evaluated in 142 patients. Combining all three factors, the ZAP-70-/CD38-/Mutated group showed the longest median TFI (62 months, n = 37), ZAP-70+/CD38+/Unmutated cases the shortest (11 months, n = 37) and cases discordant for > or = 1 factor, an intermediate TFI (27 months, n = 68) (p = 0.006). Analysis of discordant cases revealed values that were otherwise masked when measuring single prognostic factors. The presence or absence of cytogenetic abnormalities did not explain the variability among discordant cases. Simultaneous analysis of ZAP-70, CD38 and IGHV mutations in CLL provides more discriminatory prediction of TFI than any factor alone.
Original languageEnglish
Pages (from-to)2108-2115
Number of pages8
JournalLeuk Lymphoma
Issue number11
Publication statusPublished - Nov 2008


  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD38
  • Biomarkers
  • Female
  • Genes, Immunoglobulin Heavy Chain
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Male
  • Middle Aged
  • Mutation
  • Predictive Value of Tests
  • Prognosis
  • ZAP-70 Protein-Tyrosine Kinase

Fingerprint Dive into the research topics of 'Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL.'. Together they form a unique fingerprint.

Cite this